NASDAQ: CRBUCaribou Biosciences Inc Stock
$2.42+0.10 (+4.31%)
Updated Oct 31, 2025
CRBU Price
$2.42
Fair Value Price
-$1.94
Market Cap
$225.36M
52 Week Low
$0.66
52 Week High
$3.00
P/E
-1.36x
P/B
1.36x
P/S
17.32x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.77M
Earnings
-$164.26M
Gross Margin
100%
Operating Margin
-2,427.19%
Profit Margin
-2,427.1%
Debt to Equity
0.33
Operating Cash Flow
-$133M
Beta
1.82
Next Earnings
Nov 11, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CRBU Overview
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company developing genome-edited allogeneic cell therapies to treat hematologic malignancies and solid tumors. Its lead candidates are CB-010, CB-011, CB-012, and CB-020. It is collaborating with AbbVie Inc. to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CRBU's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CRBU
Ranked#153 of 488
Ranked#153 of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.65 | A | |
| $93.48 | A | |
| $14.66 | A |
Be the first to know about important CRBU news, forecast changes, insider trades & much more!
CRBU News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRBU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRBU ($2.42) is overvalued by 224.77% relative to our estimate of its Fair Value price of -$1.94 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CRBU ($2.42) is not significantly undervalued (224.77%) relative to our estimate of its Fair Value price of -$1.94 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CRBU is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CRBU due diligence checks available for Premium users.
Valuation
CRBU fair value
Fair Value of CRBU stock based on Discounted Cash Flow (DCF)
Price
$2.42
Fair Value
-$1.94
Undervalued by
224.77%
CRBU ($2.42) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CRBU ($2.42) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CRBU is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CRBU price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.36x
Industry
-9.17x
Market
41.65x
CRBU price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.36x
Industry
4.99x
CRBU is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRBU's financial health
Profit margin
Revenue
$2.7M
Net Income
-$54.1M
Profit Margin
-2,028.4%
CRBU's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CRBU's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$220.9M
Liabilities
$54.8M
Debt to equity
0.33
CRBU's short-term assets ($192.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRBU's short-term assets ($192.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRBU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$28.3M
Investing
$24.0M
Financing
$6.0k
CRBU's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CRBU vs Biotech Stocks
Caribou Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.